Health Canada
A.L. 0904A
Ottawa
K1A 0K9
Canada
Tel: 613-957-2991
Fax: 613-941-5366
Website: http://www.hc-sc.gc.ca/
Email: info@www.hc-sc.gc.ca
1217 articles about Health Canada
-
Medison Pharma Announces the Approvals by Health Canada and Therapeutics Goods Administration of KIMMTRAK® (tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma
6/8/2022
Medison Pharma is pleased to announce the approval of KIMMTRAK® by Health Canada and Therapeutics Goods Administration for the treatment of unresectable or metastatic uveal melanoma, a rare and aggressive form of melanoma that affects the eye.
-
Health Canada approves (Pr)Tabrecta®: Targeted cancer therapy for locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations
6/8/2022
Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has granted a Notice of Compliance with conditions for Tabrecta® for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer harbouring mesenchymal-epithelial transition exon 14 skipping alterations.
-
Health Canada authorizes VABYSMO® (faricimab injection) for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)
6/1/2022
Hoffmann-La Roche Limited is pleased to announce that Health Canada authorized VABYSMO® for the treatment of neovascular age-related macular degeneration and diabetic macular edema, two of the leading causes of vision loss among Canadians.
-
AB Science announces that Health Canada has started the review of New Drug Submission for masitinib in the treatment of ALS
5/26/2022
AB Science SA announces that Health Canada has issued a screening acceptance letter for the application of masitinib in the treatment of amyotrophic lateral sclerosis, meaning that the information and materials submitted by AB Science has been screened and found acceptable for review as a New Drug Submission.
-
Teleflex Announces Health Canada Approval of MANTA® Vascular Closure Device
5/18/2022
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today has announced that it received Health Canada approval for the MANTA ® Vascular Closure Device.
-
Health Canada Accepts Snds Filing and Grants Priority Review for Oral Edaravone Formulation for the Treatment of ALS
5/13/2022
Mitsubishi Tanabe Pharma Canada, Inc., a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that Health Canada has accepted the filing of a Supplement to a New Drug Submission for an investigational oral formulation of edaravone indicated for the treatment of amyotrophic lateral sclerosis.
-
Government of Canada Invests $2 million for research on innovative organ and tissue donation projects
4/29/2022
To close out National Organ Transplantation and Donation Awareness Week, the Honourable Jean-Yves Duclos, Minister of Health, announced funding for two new projects through Innovative Solutions Canada that will focus on cutting-edge research in the area of organ and tissue donation in the hopes of improving those statistics.
-
Health Canada Approves 3rd Generation Clarius Wireless Ultrasound Scanners that Connect with Apple and Android Devices
4/21/2022
Health Canada Approves 3rd Generation Clarius Wireless Ultrasound Scanners that Connect with Apple and Android Devices.
-
Health Canada Approves KEYTRUDA® (pembrolizumab) for the treatment of adult patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery
4/18/2022
Merck announced that Health Canada has granted approval for KEYTRUDA®, Merck's anti-PD-1 therapy, as a treatment for adult patients with high-risk early-stage triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery.
-
Health Canada Approves GARDASIL (Human Papillomavirus 9-valent Vaccine, Recombinant) for the Prevention of Oropharyngeal and Other Head and Neck Cancers
4/11/2022
Merck announced today that Health Canada has approved an expanded indication of
-
bioLytical Laboratories Inc. Receives Health Canada Authorization for the iStatis COVID-19 Antigen Home Test
4/2/2022
bioLytical Laboratories Inc. announced that it is launching a second test on its new platform, iStatis, after receiving Health Canada authorization for the iStatis COVID-19 Antigen Home Test for its immediate market entry into Canada.
-
Health Canada authorizes Héma-Québec submission to make source plasma donor screening criteria more inclusive for men who have sex with men
3/24/2022
Health Canada authorized a submission from Héma-Québec to change their source plasma donor screening criteria.
-
Heron Therapeutics Announces Approval of ZYNRELEF® by Health Canada for the Management of Postoperative Pain
3/17/2022
Heron Therapeutics, Inc. today announced that Health Canada has issued a Notice of Compliance (NOC) to commercialize ZYNRELEF (bupivacaine and meloxicam extended-release solution) for instillation into the surgical wound for postoperative analgesia after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty surgical procedures.
-
The Government of Canada announces additional funding to four safer supply pilot projects
3/17/2022
The evidence is clear that the COVID-19 pandemic has contributed to a worsening of the overdose crisis, which continues to affect individuals, families and communities across Canada every single day.
-
Health Canada Authorizes Moderna's COVID-19 Vaccine in Children (6-11 Years)
3/17/2022
Moderna, Inc. announced that Health Canada has approved the use of Moderna's mRNA COVID-19 vaccine, SPIKEVAX™, in a two-dose series of 50 µg per dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6 to11 years.
-
PepGen Announces Approval by Health Canada of CTA to Begin First in Human Trials of PGN-EDO51 to Treat Duchenne Muscular Dystrophy
3/15/2022
PepGen Inc. announced approval by Health Canada of PepGen’s Clinical Trial Application authorizing initiation of first-in-human trials of PepGen’s lead Enhanced Delivery Oligonucleotide candidate, PGN-EDO51.
-
Health Canada Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab)
3/10/2022
Samsung Bioepis Co., Ltd. and Biogen Canada Inc. announced that Health Canada has approved BYOOVIZ™ – a biosimilar referencing LUCENTIS®i – for the treatment of neovascular age-related macular degeneration.
-
Advisory - Pfizer recalls Accuretic blood pressure tablets due to a nitrosamine impurity
3/3/2022
Pfizer Canada ULC is recalling all lots of Accuretic medication in 10/12.5 mg, 20/12.5 mg and 20/25 mg strengths due to the presence of a nitrosamine impurity above the acceptable level.
-
BeiGene Announces Health Canada Approval for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Marginal Zone Lymphoma
3/3/2022
BeiGene Announces Health Canada Approval for BRUKINSA ® (zanubrutinib) in Relapsed or Refractory Marginal Zone Lymphoma.
-
Health Canada authorizes Medicago COVID-19 vaccine for adults 18 to 64 years of age
2/24/2022
Health Canada authorized Medicago's Covifenz COVID-19 vaccine for the prevention of COVID-19 in adults 18 to 64 years of age.